JY
ADPT icon

Jeff Yass’s Adaptive Biotechnologies ADPT Stock Holding History

Jeff Yass’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.56M Buy
166,081
+8,264
+5% +$127K ﹤0.01% 5274
2026
Q1 		$2.19M Buy
157,817
+121,002
+329% +$1.93M ﹤0.01% 5968
2025
Q4 		$598K Sell
36,815
-18,681
-34% -$305K ﹤0.01% 8383
2025
Q3 		$830K Sell
55,496
-183,094
-77% -$2.23M ﹤0.01% 7793
2025
Q2 		$2.78M Buy
238,590
+59,342
+33% +$539K ﹤0.01% 5116
2025
Q1 		$1.33M Buy
179,248
+127,683
+248% +$981K ﹤0.01% 6523
2024
Q4 		$309K Sell
51,565
-58,574
-53% -$323K ﹤0.01% 9769
2024
Q3 		$564K Sell
110,139
-284,283
-72% -$1.24M ﹤0.01% 8174
2024
Q2 		$1.43M Buy
394,422
+284,769
+260% +$904K ﹤0.01% 5774
2024
Q1 		$352K Sell
109,653
-12,207
-10% -$47.2K ﹤0.01% 9332
2023
Q4 		$597K Buy
121,860
+41,548
+52% +$190K ﹤0.01% 8224
2023
Q3 		$438K Sell
80,312
-89,722
-53% -$593K ﹤0.01% 8547
2023
Q2 		$1.14M Buy
170,034
+56,116
+49% +$417K ﹤0.01% 6370
2023
Q1 		$1.01M Buy
113,918
+85,864
+306% +$757K ﹤0.01% 6807
2022
Q4 		$214K Sell
28,054
-4,755
-14% -$37K ﹤0.01% 9961
2022
Q3 		$234K Sell
32,809
-70,176
-68% -$661K ﹤0.01% 10437
2022
Q2 		$833K Buy
102,985
+33,697
+49% +$296K ﹤0.01% 6980
2022
Q1 		$962K Buy
69,288
+26,688
+63% +$420K ﹤0.01% 7226
2021
Q4 		$1.2M Buy
42,600
+3,019
+8% +$92.5K ﹤0.01% 6817
2021
Q3 		$1.34M Sell
39,581
-52,003
-57% -$1.88M ﹤0.01% 6777
2021
Q2 		$3.74M Buy
91,584
+28,595
+45% +$1.11M ﹤0.01% 4571
2021
Q1 		$2.54M Buy
62,989
+54,337
+628% +$2.94M ﹤0.01% 5345
2020
Q4 		$512K Buy
+8,652
New +$446K ﹤0.01% 8240
2020
Q3 		– Sell
-83,373
Closed -$3.5M – 10474
2020
Q2 		$4.03M Sell
83,373
-42,253
-34% -$1.54M ﹤0.01% 3309
2020
Q1 		$3.49M Buy
125,626
+63,505
+102% +$1.77M ﹤0.01% 3059
2019
Q4 		$1.86M Buy
62,121
+20,821
+50% +$598K ﹤0.01% 4447
2019
Q3 		$1.28M Buy
+41,300
New +$1.69M ﹤0.01% 5169

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Jeff Yass's ADPT Position: Q2 2026 in Review

Jeff Yass increased its Adaptive Biotechnologies (ADPT) stake by 5.2% in Q2 2026, buying an estimated $127K and bringing the position to 166,081 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #5274.

Jeff Yass first reported a position in ADPT in Q3 2019 and has held it in 27 quarters since. The position peaked at $4.03M in Q2 2020. 298 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Jeff Yass held 166,081 shares of Adaptive Biotechnologies worth $3.56M as of Q2 2026.
  • Jeff Yass bought 8,264 Adaptive Biotechnologies shares in Q2 2026, an estimated $127K.
  • Adaptive Biotechnologies made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5274 holding.
  • Jeff Yass first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 27 quarters since.
  • Jeff Yass's Adaptive Biotechnologies position peaked at $4.03M in Q2 2020.
  • 298 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.